Abstract
Improving outcomes for the growing early-stage patient pool requires developing adjuvant non-surgical therapeutic strategies, which have been traditionally focused on late-stage NSCLC. Metformin, a widely used type II diabetes drug with a long history of safety and minimal side effects, is also known to show anti-cancer activity. We have previously demonstrated that the anti-cancer effects metformin in stage I NSCLC is dependent on patient Body mass index (BMI). To gain insight into the molecular mechanism responsible for these context-dependent effects, we sought to model the effects of high-BMI status and metformin in a mouse model of lung cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
